Literature DB >> 28454683

The Importance of Prolonged Provocation in Drug Allergy - Results From a Danish Allergy Clinic.

Sara Fransson1, Holger Mosbech2, Mogens Kappel2, Janni Hjortlund2, Lars K Poulsen2, Ask D Kvisselgaard2, Lene H Garvey2.   

Abstract

BACKGROUND: Drug provocation is the "Gold Standard" in drug allergy investigation. Recent studies suggest that a negative drug provocation on first dose should be followed by a prolonged provocation over several days.
OBJECTIVE: To evaluate drug allergy investigations on the basis of drug provocation, including prolonged provocation.
METHODS: Data from adult patients investigated for drug allergy in a Danish Allergy Clinic during the period 2010 to 2014 were entered into a database. Data included clinical details and results of provocations with suspected culprit drug (for penicillins performed only in specific IgE-negative patients). If provocation was negative on first dose, treatment was continued for 3 to 10 days.
RESULTS: A total of 1,913 provocations were done in 1,659 patients, median age 46 years, of whom 1,237 (74.6%) were females. Drugs investigated were antibiotics, 1,776 (92.8%), of which 1,590 (89.5%) were penicillins; analgesics, 59 (3.1%); local anesthetics, 33 (1.7%); and other drugs, 45 (2.4%). In total, 211 of 1,913 (11.0%) provocations were positive. Causes were antibiotics, 198 (93.8%), of which 167 (84.3%) were penicillins; analgesics, 7 (3.3%); local anesthetics, 0; and other drugs, 6 (2.8%). Only 43 (20.4%) provocations were positive on first dose, whereas 95 (45.0%) turned positive more than 3 days later.
CONCLUSIONS: Only 11.0% of the provocations were positive. Importantly, only 1 of 5 patients tested positive on the first dose, indicating that prolonged exposure should always be considered when drug provocation is included in allergy investigations. Most provocations were with penicillins, reflecting the pattern of antibiotic use in Denmark, which differs from that in other countries, especially outside Northern Europe.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Betalactam antibiotics; Drug allergy; Drug challenge; Drug provocation test; Narrow-spectrum penicillin; Prolonged provocation

Mesh:

Substances:

Year:  2017        PMID: 28454683     DOI: 10.1016/j.jaip.2017.02.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  Prospective study of 5-day challenge with penicillins in children.

Authors:  Birgitte Tusgaard Petersen; Josefine Gradman
Journal:  BMJ Paediatr Open       Date:  2020-08-04

2.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 3.  Pro and Contra: Provocation Tests in Drug Hypersensitivity.

Authors:  Ozge Soyer; Umit Murat Sahiner; Bulent Enis Sekerel
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

4.  Identifying drug allergies by means of exposure testing - the frequency and nature of hypersensitivity reactions.

Authors:  Tobias Welponer; Matthias Brandlmaier; Bernd Feuerstein; Johann W Bauer
Journal:  Postepy Dermatol Alergol       Date:  2021-11-01       Impact factor: 1.664

5.  Simplifying the drug provocation test in non-immediate hypersensitivity reactions to amoxicillin in children: The experience of a tertiary care allergy unit.

Authors:  Giulia Liccioli; Mattia Giovannini; Jean-Christoph Caubet; Simona Barni; Lucrezia Sarti; Paola Parronchi; Manuela Capone; Leonardo Tomei; Francesca Mori
Journal:  Pediatr Allergy Immunol       Date:  2022-06       Impact factor: 5.464

6.  Heterogeneity in direct oral penicillin challenge protocols in penicillin allergy de-labelling.

Authors:  Rashmeet Bhogal; Abid Hussain; Louise Savic; Siraj A Misbah; Ariyur Balaji; Chidanand Hullur; John F Marriott; Mamidipudi T Krishna
Journal:  Infect Prev Pract       Date:  2021-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.